Cardiovascular and neurological toxicity of venlafaxine

Human and Experimental Toxicology

Volumn 18, Issue 5, 1999, Pages 309-313

  Blythe, David ^a   Hackett, L Peter ^b  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b Western Australian Centre for Pathology and Medical Research   (Australia)

Author keywords

Cardiotoxicity; Neurotoxicity; Pharmacokinetics; Venlafaxine

Indexed keywords

CYTOCHROME; VENLAFAXINE;

ADULT; ARTICLE; CARDIOTOXICITY; CASE REPORT; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; FEMALE; HUMAN; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; CARDIOVASCULAR SYSTEM; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; KIDNEY; METABOLIC CLEARANCE RATE; OVERDOSE; PHENOTYPE;

EID: 0033019369     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032799678840165     Document Type: Article

References (22)

1. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. Journal of Clinical Psychiatry 1995; 56: 574-579.
2. Fantaskey A, Burkhart KK. A case report of venlafaxine toxicity. Journal of Toxicology and Clinical Toxicology 1995; 33: 359-361.
3. White CM, Gailey RA, Levin GM, Smith T. Seizure resulting from a venlafaxine overdose. Annals of Pharmacotherapy 1997; 31: 178-180.
4. Ilett KF et al. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. British Journal of Clinical Pharmacology 1998; 45: 459-462.
5. Troy SM, Parker VD, Fruncilli RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. Journal of Clinical Pharmacology 1995; 35: 404-409.
6. Troy SM et al. Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. Journal of Clinical Pharmacology 1995; 35: 410-419.
7. Parsons AT, Anthony RM, Meeker JE. Two fatal cases of venlafaxine poisoning. Journal of Analytical Toxicology 1996; 20: 266-268.
8. Klamerus KJ et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. Journal of Clinical Pharmacology 1992; 32: 716-724.
9. Holliday SM, Benfield P. Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280-294.
10. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clinical Pharmacokinetics 1995; 29: 192-209.
11. Troy SM et al. The effect of renal disease on the disposition of venlafaxine. Clinical Pharmacology & Therapeutics 1994; 56: 14-21.
12. Schweizer E, Feighner JP, Mendos LA, Richels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychopharmacology 1994; 55: 104-108.
13. Clerc GE, Ruimy D, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalised for major depression and melancholia. International Clinics in Psychopharmacology 1994; 9: 139-143.
14. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. Journal of Clinical Psychopharmacology 1996; 16 (2 supp 3): 54S-59S.
15. Morton WA, Sonne SC, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Annals of Pharmacotherapy 1995; 29: 387-395.
16. Saletu B et al. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. British Journal of Clinical Pharmacology 1992; 33: 589-601.
17. Data on file, 1993. Wyeth-Ayerst Laboratories, Philadelphia PA 19101.
18. Setzer SC. Acute venlafaxine overdose - a multicentre study. North American Congress in Clinical Toxicology Abstract 27. Clinical Toxicology 1995; 33: 496-497.
19. Banham ND. Fatal venlafaxine overdose. Medical Journal of Australia 1998; 169: 445-448.
20. Coorey AN, Wenck DJ. Venlafaxine overdose. Medical Journal of Australia 1998; 168: 523.
21. Roxanas MG, Machado JFD. Serotonin syndrome in combined moclobemide and venlafaxine ingestion. Medical Journal of Australia 1998; 168: 523-524.
22. Zhalkovsky B. Seizure activity and enzyme elevations after venlafaxine overdose. Journal of Clinical Psychopharmacology 1997; 17(6): 490-491.